Compare BCAL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAL | CTMX |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.3M | 596.2M |
| IPO Year | 2020 | 2015 |
| Metric | BCAL | CTMX |
|---|---|---|
| Price | $17.61 | $4.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $20.50 | $11.90 |
| AVG Volume (30 Days) | 158.4K | ★ 9.4M |
| Earning Date | 04-23-2026 | 03-16-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ 777.27 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.67 | $27.22 |
| P/E Ratio | ★ $8.98 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.88 | $0.40 |
| 52 Week High | $20.47 | $8.21 |
| Indicator | BCAL | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 44.37 |
| Support Level | $16.87 | $3.55 |
| Resistance Level | $19.31 | $6.20 |
| Average True Range (ATR) | 0.45 | 0.60 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 46.43 | 3.23 |
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.